Last month, PPMD’s Founding President & CEO Pat Furlong presented at the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, addressing the use of digital health technologies to improve therapeutic research and development.

More specifically, Pat spoke about the importance of exploring digital measures as a tool to more accurately capture functional data, such as stride velocity, in people with Duchenne. 95th Percentile Stride Velocity has been accepted by the European Medical Agency for use as a secondary endpoint in clinical trials and we are hopeful the data will be submitted to the FDA soon.

PPMD continues to explore the latest technologies, looking for innovative ways to better understand and capture data to increase our knowledge of disease progression in Duchenne.

Click here to download Pat’s presentation.